Drospirenone's 24/4 Pill for PMDD: Reading the Three-Cycle Trial

The US indication for Yaz includes PMDD symptoms in people who choose an oral contraceptive for birth control. Its labeling says effectiveness for PMDD beyond three menstrual cycles has not been evaluated.¹ Discuss both contraception and symptom relief with your prescriber.

What counted as a response?

A 2005 multicenter, double-blind randomized trial² assigned 450 women to placebo or a pill containing drospirenone 3 mg and ethinyl estradiol 20 micrograms. Participants charted symptoms daily during two preliminary cycles and three treatment cycles. The tested schedule was 24 hormone-containing pills followed by four inactive pills.²

A responder had at least a 50% decrease in daily symptom scores. That occurred in 48% of the treatment group and 36% of the placebo group. The difference was about 12 percentage points, or roughly 12 additional responders per 100 treated under those study conditions. Response did not mean every symptom disappeared.²

The total Daily Record of Severity of Problems score also fell more with the pill: an adjusted difference of 7.5 points compared with placebo. This was a symptom-rating outcome over three cycles, not a comparison against another contraceptive or an antidepressant.²

What the later review added

The 2023 Cochrane review included five randomized trials and 858 women, most with PMDD. It searched through June 2022. The reviewers found small-to-moderate benefits for premenstrual symptoms and associated difficulties with productivity, social activities and relationships, alongside a substantial placebo response. Evidence for overall symptom improvement was rated low quality. Its study table identifies Berlex, now Bayer, as the 2005 trial²’s funder.³

More participants withdrew because of side effects. Cochrane estimated that, assuming a 3% withdrawal risk with placebo, the corresponding risk with drospirenone plus estrogen would be 6% to 16%. That range is an estimate from pooled evidence, rather than a prediction for one person.³

The review could not establish whether benefit continues beyond three cycles, applies to milder symptoms, or exceeds that of other combined pills. Those uncertainties matter if you have already tried a different pill. They also prevent treating this evidence as proof that every drospirenone formulation or schedule has the same effect.³

The safety review comes before a prescription

The Yaz label warns that smokers over 35 should not use it. Contraindications include kidney impairment, adrenal insufficiency and high clotting risk. It notes that drospirenone-containing combined pills may carry more venous clot risk than pills containing levonorgestrel.¹

Drospirenone can raise potassium. The label calls for first-cycle potassium testing with certain daily, long-term medicines that raise potassium, including spironolactone and potassium supplements. It also calls for close observation with a depression history. Bring a complete medicine list and discuss your health history.¹

Give the review appointment something to measure

The label describes diagnosis using symptom ratings recorded prospectively over at least two cycles.¹ Ask which diary or questionnaire your clinician wants. Record symptoms on the better days too, so the timing can be assessed rather than reconstructed from memory.

For a proposed treatment trial, agree on the symptoms and activities you want to improve. Instead of recording only “bad day,” describe the interruption: leaving work early, missing a class, arguing with a partner or being unable to concentrate. Keep side effects in a separate column so an improving symptom score does not hide a treatment you find difficult to tolerate.

Before leaving, get answers to three questions:

• When will we review benefit, side effects and whether I want to continue?
• What mood changes or physical symptoms need contact before that date?
• How should I handle missed pills, vomiting or diarrhea while maintaining contraception?

Use the prescribed schedule and pack instructions. The three-cycle evidence limit is a reason to plan review, not an instruction to stop automatically after the third pack.

The Visit Script in Period, Handled asks you to describe when a change began, what it stopped you doing and the question you want answered. Those prompts can organize the appointment; the daily PMDD ratings and treatment plan should come from your clinical team.